Niraparib in Combination With Dostarlimab in Patients With Recurrent or Progressive Cervix Cancer
Status:
Recruiting
Trial end date:
2025-07-01
Target enrollment:
Participant gender:
Summary
The purpose of this research study is to test the safety of Niraparib and dostarlimab as a
combination treatment and see what effects (good and bad) this combination treatment has on
patients with recurrent or progressive cervix cancer.